Search
01/12/2023
Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis
Balsa A., Díaz del Campo Fontecha P., Silva Fernández L., Valencia Martín J., Nistal Martínez V., León Vázquez F., Hernández Hernández M.V., Corominas H., Cáliz Cáliz R., Aguado García J.M., Candelas Rodríguez G., Ibargoyen Roteta N., Martí Carbajal A., Plana Farras M.N., Puñal Riobóo J., Park H.S., Triñanes Pego Y., Villaverde García V.. Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis. Reumatologia Clinica. 2023; 19(10)DOI:10.1016/j.reuma.2023.07.001. PMID:. IF:(Q/D).
24/11/2023
Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
Sainz, L, Riera, P, Moya, P, Bernal, S, Casademont, J, Diaz-Torne, C, Millan, AM, Park, HS, Lasa, A, Corominas, H. Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis. ARTHRITIS RESEARCH & THERAPY. 2023; 25(1)DOI:10.1186/s13075-023-03209-1. PMID:38001504. IF:4.400(Q1/3D).
23/10/2023
Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
Valero-Martínez, C, Urgelles, JF, Sallés, M, Joven-Ibáñez, BE, de Juanes, A, Ramírez, J, Juanola, X, Almodóvar, R, Laiz, A, Moreno, M, Pujol, M, Beltrán, E, Pinto-Tasende, JA, Crespí, L, Sala-Icardo, L, Castañeda, S, García-Vicuña, R. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1283251. PMID:37936691. IF:5.700(Q1/3D).
01/07/2023
Impaired Regulation by IL-35 in Systemic Sclerosis
Osuna-Gomez, R, Castellvi, I, Mulet, M, Ortiz, MA, Brough, DE, Sabzevari, H, Semnani, RT, Vidal, S. Impaired Regulation by IL-35 in Systemic Sclerosis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(13)DOI:10.3390/ijms241310567. PMID:37445745. IF:4.900(Q1/3D).
01/06/2023
Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register (vol 8, e002507, 2022)
De Miguel, E, Sanchez-Costa, JT, Estrada, P, Munoz, A, Martinez, CV, Alvarado, PM, Garcia-Villanueva, MJ, Angeles, VAN, Da Veiga, CGL, Frutos, AR, Ivorra, JAR, Arrabal, SL, Rocha, MV, Iniguez, CL, Garcia-Gonzalez, M, Molina-Almela, C, Villar, MA, Mas, AJ, Gonzalez-Gay, MA, Blanco, R. Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register (vol 8, e002507, 2022). RMD Open. 2023; 9(2)DOI:10.1136/rmdopen-2022-002507corr1. PMID:. IF:5.100(Q1/2D).
01/06/2023
Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set
Morillon, MB, Norup, A, Singh, JA, Dalbeth, N, Taylor, WJ, Kennedy, MA, Pedersen, BM, Grainger, R, Tugwell, P, Perez-Ruiz, F, Diaz-Torne, C, Edwards, NL, Shea, B, Ellingsen, TJ, Christensen, R, Stamp, LK. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set. SEMINARS IN ARTHRITIS AND RHEUMATISM. 2023; 60DOI:10.1016/j.semarthrit.2023.152191. PMID:36963128. IF:4.600(Q1/2D).